|
|
||||||||
Papers In Press, published online ahead of print May 16, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General Internal Medicine, Leiden University Medical Center, Leiden 2300 RC
Corresponding Author: a.h.m.smelt{at}lumc.nl
Hypertriglyceridemia (HTG) is associated with insulin resistance, increased cholesteryl ester transfer (CET) and low HDL-cholesterol (HDL-C). Phospholipid transfer protein (PLTP) may be involved in these relationships. Associations between CET, lipids, insulin resistance, CETP- and PLTP activities and PLTP mass were investigated in 18 HTG patients and 20 controls. The effects of 6-weeks bezafibrate treatment on these parameters were studied in a randomized controlled trial in HTG patients. HTG patients had significantly higher serum triglycerides, insulin resistance, FFA and CET, lower levels of HDL-C (-44%) and PLTP mass (-54%), and higher CETP (+20%) and PLTP activities (+48%), compared to controls. Bezafibrate significantly reduced serum triglycerides, CET (-37%), insulin resistance (-53%), FFA (-48%), CETP activity (-12%), PLTP activity (-8%) and increased HDL-C (+27%), whereas PLTP mass remained unchanged. Regression analysis showed a significant positive contribution of PLTP mass (p=0.001) but not of PLTP activity to HDL-C, whereas insulin resistance positively contributed to PLTP activity levels (p<0.01). Bezafibrate-induced change in CET and HDL-C levels correlated significantly with changes in CETP activity and FFA levels, but not with a change in PLTP activity. Bezafibrate-induced change in PLTP activity correlated with change in FFA levels (r=0.455, p=0.058). We propose that the elevated PLTP activity in HTG is related to insulin resistance and not to increased PLTP mass. Bezafibrate-induced diminished insulin resistance is associated with a reduction of both CET and PLTP activity.
Revised on May 2, 2003
Accepted on May 2, 2003
Decreased PLTP mass but elevated PLTP activity, linked to insulin resistance, in hypertriglyceridemia: effects of bezafibrate therapy
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
H. Samyn, M. Moerland, T. van Gent, R. van Haperen, J. Metso, F. Grosveld, M. Jauhiainen, A. van Tol, and R. de Crom Plasma phospholipid transfer activity is essential for increased atherogenesis in PLTP transgenic mice: a mutation-inactivation study J. Lipid Res., December 1, 2008; 49(12): 2504 - 2512. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. P F Dullaart, A. K Groen, G. M Dallinga-Thie, R. de Vries, W. J Sluiter, and A. van Tol Fibroblast cholesterol efflux to plasma from metabolic syndrome subjects is not defective despite low high-density lipoprotein cholesterol Eur. J. Endocrinol., January 1, 2008; 158(1): 53 - 60. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. C. van der Hoogt, W. de Haan, M. Westerterp, M. Hoekstra, G. M. Dallinga-Thie, J. A. Romijn, H. M. G. Princen, J. W. Jukema, L. M. Havekes, and P. C. N. Rensen Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression J. Lipid Res., August 1, 2007; 48(8): 1763 - 1771. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. M. Dallinga-Thie, A. van Tol, H. Hattori, P. C.N. Rensen, E. J.G. Sijbrands, and for the Diabetes Atorvastatin Lipid Intervention ( Plasma phospholipid transfer protein activity is decreased in type 2 diabetes during treatment with atorvastatin: a role for apolipoprotein e? Diabetes, May 1, 2006; 55(5): 1491 - 1496. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Ji, G. F. Watts, A. G. Johnson, D. C. Chan, E. M. M. Ooi, K.-A. Rye, A. P. Serone, and P. H. R. Barrett High-Density Lipoprotein (HDL) Transport in the Metabolic Syndrome: Application of a New Model for HDL Particle Kinetics J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 973 - 979. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. T. Janis, S. Siggins, E. Tahvanainen, R. Vikstedt, K. Silander, J. Metso, A. Aromaa, M.-R. Taskinen, V. M. Olkkonen, M. Jauhiainen, et al. Active and low-active forms of serum phospholipid transfer protein in a normal Finnish population sample J. Lipid Res., December 1, 2004; 45(12): 2303 - 2309. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. Witte, M. R. Taskinen, H. Perttunen-Nio, A. van Tol, S. Livingstone, and H. M. Colhoun Study of agreement between LDL size as measured by nuclear magnetic resonance and gradient gel electrophoresis J. Lipid Res., June 1, 2004; 45(6): 1069 - 1076. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |